Quia Pharma (DB:99B0) - Stock Price, News & Analysis

99B0 Stock Overview

Engages in the research, development, and commercialization of medicines based on Uni-Qleaver, a drug delivery platform.

About the company

99B0 fundamental analysis
Snowflake Score
Valuation	0/6
Future Growth	0/6
Past Performance	0/6
Financial Health	2/6
Dividends	0/6

Rewards

Risk Analysis

Has less than 1 year of cash runway

Does not have a meaningful market cap (€59M)

Makes less than USD$1m in revenue (SEK4M)

Highly volatile share price over the past 3 months

+ 2 more risks

Quia Pharma AB (publ) Competitors

co.don

XTRA:CNW

€6.5m

Paion

XTRA:PA8

€2.6m

Medigene

XTRA:MDG1

€32.4m

Bellicum Pharmaceuticals

BST:BPXA

€772.4k

Price History & Performance

Summary of all time highs, changes and price drops for Quia Pharma
Historical stock prices
Current Share Price	SEK 0.0027
52 Week High	SEK 0.02
52 Week Low	SEK 0.0001
Beta	0.72
11 Month Change	-12.90%
3 Month Change	-48.08%
1 Year Change	-81.25%
33 Year Change	-99.96%
5 Year Change	n/a
Change since IPO	-99.98%

Recent updates

Shareholder Returns

	99B0	DE Biotechs	DE Market
7D	-3.6%	2.6%	1.5%
1Y	-81.3%	-20.4%	4.2%

Return vs Industry: 99B0 underperformed the German Biotechs industry which returned -19.7% over the past year.

Return vs Market: 99B0 underperformed the German Market which returned 4.9% over the past year.

Price Volatility

Is 99B0's price volatile compared to industry and market?
99B0 volatility
99B0 Average Weekly Movement	28.7%
Biotechs Industry Average Movement	5.8%
Market Average Movement	4.9%
10% most volatile stocks in DE Market	11.2%
10% least volatile stocks in DE Market	2.5%

Stable Share Price: 99B0's share price has been volatile over the past 3 months.

Volatility Over Time: 99B0's weekly volatility has decreased from 1642% to 29% over the past year, but is still higher than 75% of German stocks.

About the Company

Founded	Employees	CEO	Website
2004	3	Marcus Bosson	www.quiapeg.com

Quia Pharma AB (publ) engages in the research, development, and commercialization of medicines based on Uni-Qleaver, a drug delivery platform. The company develops drugs through its pegylation technology platform. Its product pipeline includes QPG-1030 (pegylated teduglutide) for the treatment of short bowel syndrome, and QPG-1029 under pre-clinical development for stable plasma concentration, as well as antibody-drug conjugates being developed using the company’s Uni-Qleaver technology-platform.

Quia Pharma AB (publ) Fundamentals Summary

How do Quia Pharma's earnings and revenue compare to its market cap?
99B0 fundamental statistics
Market cap	€5.16m
Earnings (TTM)	-€1.46m
Revenue (TTM)	€385.51k

13.4x

P/S Ratio

-3.5x

P/E Ratio

Is 99B0 overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
99B0 income statement (TTM)
Revenue	SEK 4.37m
Cost of Revenue	SEK 2.20m
Gross Profit	SEK 2.17m
Other Expenses	SEK 18.69m
Earnings	-SEK 16.52m

Last Reported Earnings

Dec 31, 2023

Next Earnings Date

n/a

Earnings per share (EPS)	-0.011
Gross Margin	49.63%
Net Profit Margin	-377.75%
Debt/Equity Ratio	135.1%

How did 99B0 perform over the long term?

See historical performance and comparison

Quia Pharma DB:99B0 Stock Report